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Abstract
Background:  Tyrosinemia type I, the most severe disease of the tyrosine catabolic pathway is
caused by a deficiency in fumarylacetoacetate hydrolase (FAH). A patient showing few of the
symptoms associated with the disease, was found to be a compound heterozygote for a splice
mutation, IVS6-1g->t, and a putative missense mutation, Q279R. Analysis of FAH expression in liver
sections obtained after resection for hepatocellular carcinoma revealed a mosaic pattern of
expression. No FAH was found in tumor regions while a healthy region contained enzyme-
expressing nodules.
Results:  Analysis of DNA from a FAH expressing region showed that the expression of the
protein was due to correction of the Q279R mutation. RT-PCR was used to assess if Q279R RNA
was produced in the liver cells and in fibroblasts from the patient. Normal mRNA was found in the
liver region where the mutation had reverted while splicing intermediates were found in non-
expressing regions suggesting that the Q279R mutation acted as a splicing mutation in vivo.
Sequence of transcripts showed skipping of exon 8 alone or together with exon 9. Using minigenes
in transfection assays, the Q279R mutation was shown to induce skipping of exon 9 when placed
in a constitutive splicing environment.
Conclusion:  These data suggest that the putative missense mutation Q279R in the FAH gene acts
as a splicing mutation in vivo. Moreover FAH expression can be partially restored in certain liver
cells as a result of a reversion of the Q279R mutation and expansion of the corrected cells.
Background
Tyrosinemia type I (HTI, McKusick 276700) is an auto-
somal recessive disease caused by a deficiency in fumar-
ylacetoacetate hydrolase (FAH, EC 3. 7. 1. 2), the last
enzyme of the catabolic pathway of tyrosine [1,2,3,4]. In
the absence of FAH, metabolites such as maleylacetoac-
etate (MAA), fumarylacetoacetate (FAA), and succiny-
lacetone (SAc) accumulate during tyrosine degradation.
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mammalian cell assay [5], to induce cell cycle arrest at
G2/M, and apoptosis [6]. Tyrosinemia is characterized
by hepatic failure, cirrhosis, renal dysfunction, hepato-
carcinoma, and neurologic crisis. Liver is the most se-
verely affected organ. Two distinct forms of the disease
have been described according to the symptoms and age
of onset [7, 8]. The acute form of tyrosinemia is diag-
nosed in the first months of life and results in rapid dete-
rioration of hepatic and renal functions leading to early
death due to hepatic failure. In the chronic form, symp-
toms appear later in childhood and often culminate with
development of hepatocarcinomas. Molecular studies on
some patients presenting either the acute or the chronic
form revealed identical genotypes [9] suggesting that
genotypic variability does no account alone for the differ-
ent clinical forms observed in tyrosinemia.
The gene encoding the FAH protein has been cloned and
mapped to chromosome 15, region q23-q25 [10]. It con-
tains 14 exons, spanning over 35 kb of DNA [11]. At this
time, 34 different mutations of the FAH gene have been
identified in HTI patients: 18 missense mutations, 5 non-
sense mutations, and 10 splicing mutations [4, 12]. One
mutation (R341W) causes a pseudodeficient phenotype
with a reduced amount of FAH immunoreactive material
[13]. FAH is a cytoplasmic homodimeric enzyme. Its
crystal structure shows that each subunit of 46 kDa con-
sists of a 120 residue N-terminal domain and a 300 resi-
due C-terminal domain. These subunits interact through
their C-terminal domains and the active site is located in
close proximity to the dimer interface [14]. It has been
shown that the FAH active site, which is highly con-
served from fungi to human, comprises two metal ions
that participate in substrate binding and catalysis.
Recently, Kim et al. [15] described the case of a HTI pa-
tient who showed few of the symptoms associated with
HTI until the age of 37 when hepatocellular carcinoma
was diagnosed. This patient is one of the few reported
cases of HTI who lived over 30 years and has been geno-
typed as a compound heterozygote for a frequent splice
mutation, IVS6-1g->t, and a new mutation, Q279R
(836A->G). Since this patient showed an almost normal
phenotype during the first 36 years of her life, a molecu-
lar analysis of both mutations was carried out in vivo and
in vitro to determine if this particular phenotype was
caused by a neutral missense mutation (Q279R) like in
the pseudodeficiency phenotype or by other mechanisms
such as mutation reversion, as described in a number of
HTI patients [16]. It was shown that FAH was expressed
in a mosaic pattern in the patient's liver, with non-tu-
moral regions expressing FAH [15]. Here we report that
the Q279R mutation acts as a splicing mutation in vivo
and that correction of this mutation in some cells leads to
restored FAH function and partial liver repopulation by
corrected cells.
Results
Expression of FAH in a non-tumoral liver region results 
from reversion of the Q279R mutation
Immunostaining of sections from the resected liver of
the HTI patient with an anti-FAH antibody showed a
mosaic pattern of FAH reactivity [15]. The non-tumoral
region was FAH immunopositive and expressed full-
length FAH as demonstrated by western blot analysis, in
contrast to tumoral regions where no FAH was detected
(no truncated protein form was detected either [15]).
Spectrophotometric measurement of FAH hydrolytic ac-
tivity against FAA in microdissected regions of frozen liv-
er sections confirmed that the enzyme expressed in the
non-tumoral region was active (data not shown). The
DNA in microdissected regions of liver sections was next
examined in order to determine whether one of the two
mutations had reverted (Figure 1). Restriction enzyme
analysis revealed that DNA extracted from tumor regions
presented both the IVS6-1g->t and Q279R mutations. As
for the DNA extracted from a FAH positive nodule (NT),
it showed the pattern expected for IVS6-1g->t heterozy-
gocity (three bands of 156-, 104- and 75-bp, Figure 1). In
the Q279R test, a weak mutated band (58-bp) was de-
tected along with a strong band of normal length (78-bp)
indicating the presence of a normal allele likely resulting
from a reversion of the mutation (Figure 1, lane NT). Re-
version of the Q279R mutation to Q279Q on one FAH al-
lele was confirmed by direct sequencing (see below).
The Q279R mutation is associated with altered mRNA 
splicing in vivo
In order to determine if Q279R-containing mRNA was
present in liver cells, we used RT-PCR to examine the
transcripts in various liver specimens and in fibroblasts
of the patient (Figure 2). Interestingly, RT-PCR amplifi-
cation of transcripts showed an unexpected alternative
splicing pattern in different liver regions. Thus in a FAH
expressing nodule (NT) the main amplified band was of
a length expected for a normal mRNA (537-bp, Figure
2A). Indeed the sequence of this major product was iden-
tical to wild-type FAH mRNA, without neither the
Q279R nor the IVS6-1g->t mutation (data not shown).
The amplified products of transcripts from the FAH neg-
ative region of a tumor section presented three bands of
slightly lower molecular weight (Figure 2A, lane 3), as
observed in the patient's fibroblasts (lane 4). Cloning
and sequencing of the fragments amplified from the tu-
mor region revealed 7 mRNA species (summarized in
Figure 3). The largest band in the tumoral region actually
comprises two transcripts that comigrate, as determined
by cloning and sequencing. One includes a 5-bp deletion
BMC Genetics (2001) 2:9 http://www.biomedcentral.com/1471-2156/2/9(del5, 532-bp) at the beginning of exon 7, and the other,
the same deletion together with another 13-bp deletion
at the beginning of exon 8 (del5+del13, 519-bp). The sec-
ond band (about 400-bp) observed in the tumoral region
also consists of two transcripts, the first one with the 5-
bp deletion in exon 7 and a skipping of exon 8
Figure 1
Mutation analysis in different liver regions. DNA was extracted from different liver regions and amplified by PCR. PCR prod-
ucts were digested with either Alu I to detect IVS6-1g->t or with Msp I to detect Q279R. For IVS6-1 g->t, the same hetero-
zygous pattern is seen in both the reverted nodule (NT), tumor section (T) and fibroblast DNA (F), showing 3 bands, one at
156-, another at 104- and the last at 75-bp. The control (wt/wt) shows two bands, one at 156- and the other at 75-bp, indicat-
ing the absence of IVS6-1g->t (M: molecular weight marker, 100- and 200-bp). For Q279R both the 78- and 58-bp bands are
seen in the tumor section (T) and fibroblast DNA (F) indicating an heterozygous genotype while only the 78-bp wild-type band
is seen in the control (wt/wt). In the region suspected of reversion (NT), a strong 78-bp wild-type band is seen with a weak 58-
bp mutated band (M: molecular weight marker, 100-bp).
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RT-PCR on RNA from different liver sections and fibroblasts. Total RNA was extracted from various samples, reverse tran-
scribed and amplified by PCR. The 537-bp fragment starts in the middle of exon 6 and ends in the middle of exon 12. A- RT-
PCR products amplified from total RNA extracted from different liver regions i.e. non-tumoral (lane 2) and tumoral (lane 3)
and from fibroblasts of the patient (lane 4). (lane 1: Control RNA from T19-EBV normal cells). B- RT-PCR products amplified
from total RNA extracted from transformed lymphocytes of the parents (father; lane 1, mother; lane 2) and cultured fibrob-
lasts of another patient homozygous for IVS6-1g->t (lane 3). A normal length cDNA is seen in the reverted nodule (537-bp, A,
lane 2) and in both parents. Three of the products seen in the tumor liver section (A, lane 3) are also observed in a patient
homozygous for the IVS6-1g->t mutation (B, lane 3).
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which is a product of the Q279R mutation (see below).
These first three transcripts were already reported for
the IVS6-1g->t mutation [17], (see , Figure 2B, lane 3).
Figure 3
Diagram of RNA alternative transcripts found in the IVS6-1g->t and Q279R patient.The splicing pattern is based on sequence
analysis of the RT-PCR transcription products amplified with the primers Tan5 and Tan 51. The alternative transcripts identi-
fied are pictured from exons 6 to 10 (represented by boxes). The introns are represented by lines. Black boxes indicate that a
cryptic splice site is activated with a subsequent skipping of exonic sequences. Premature stop codons that appear due to
frameshift are represented by a stop sign.
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the RT-PCR product from the tumoral region and con-
sists in retention of intron 6 (InsI6, see lane 3, Figure
2B).
The other three products identified by cloning and se-
quencing of the PCR products from the tumoral region
seem to be a consequence of the Q279R allele, with two
of them resulting from alternative splicing (see Figure 2
and the diagram of Figure 3). The first one is a transcript
with a skipping of exon 8 (del100, 437-bp), which comi-
grates with the del5+del100 transcript. The second one
results from the skipping of both exons 8 and 9 (del231,
306-bp). The last transcript identified (537-bp, see lane
1, Figure 2B) and due to the Q279R paternal allele is of
normal length and contains the Q279R mutation in exon
9.
Four of the six alternative transcripts identified in the tu-
moral region of the patient are caused by the IVS6-1g->t
mutation (InsI6, del5, del5+del13, del5+del100). The
other two alternative transcripts (del100, and del231)
seem to be due to the Q279R allele. This is summarized
in the diagram of Figure 3. Del231, which lacks both ex-
ons 8 and 9, is a major product. These data suggest that
the Q279R mutation disturbs the splicing pattern in vi-
vo.
Q279R acts as a splicing mutation in a minigene assay
To test whether the Q279R mutation is itself a splicing
mutation, we constructed two minigenes in which a wild-
type exon 9 of the FAH gene or an exon 9 with the Q279R
mutation was placed in a constitutive splicing context.
Reed [18] has previously reported that exon recognition
would require an mRNA region of about 300-bp includ-
ing the exon itself and the adjacent intronic sequences. A
387-bp fragment comprising the wild-type or the mutat-
ed exon 9 and their surrounding intronic sequences was
amplified and inserted in a globin splicing cassette (see
Methods, Figure 4A). Both minigenes were sequenced
prior to transient transfection in HeLa cells. Total RNA
was then amplified with the HG1S and HG3AS primers,
which are located at each end of the splicing cassette (see
Figure 4A).
As shown in Figure 4B, the major product of Q279Q-K7
is of the expected size and the two globin exons and the
fah exon 9 are correctly spliced together. This was con-
firmed by sequencing. In contrast, the major product of
Q279R-K7 is of lower size. In this case, the β-globin ex-
ons are joined together and exon 9 is skipped from the
mature transcript. These results strongly argue that the
Q279R mutation acts as a splicing mutation. Of impor-
tance is the presence of a small but significant amount of
spliced forms containing the mutated exon 9 (Figure 4B).
This observation is consistent with the presence of a low
fraction of normally spliced mRNA species in the patient
specimens (see above).
Discussion
The observation of FAH mosaicism in the liver of a HTI
patient led us to suspect that reversion of one of the mu-
tations might have occurred, as reported in patients with
other mutations [9, 16]. This proved to be the case as
confirmed by the mutation detection test in different re-
gions of the liver. The heterozygocity pattern found in the
tumoral region was no longer present in the non-tumoral
normal looking section of the patient liver. The site-spe-
cific reversion of the Q279R mutation in this region was
also demonstrated by direct sequencing. This event leads
to both the production of normal sized FAH mRNA and
expression of functional FAH, as shown by western blot
and enzymatic activity measurements. FAH positive cells
have been reported to show a selective growth advantage
in vivo. Overturf et al. [19] showed that the introduction
of as few as 1000 normal or corrected hepatocytes in a
FAH knock-out mice model led to an extensive repopula-
tion of the liver. Therefore, in man, a reversion event
might occur in a cell, which expands and forms FAH ex-
pressing nodule. The amount of FAH being expressed by
those reverted cells appears to be sufficient to reduce the
symptoms of HTI. Kelsey et al. [20] showed that the ex-
pression of levels as low as 2% of the FAH level in normal
liver was sufficient to rescue the lethal phenotype in the
albino mouse model of HTI.
In the present patient, cancer is only present in non-FAH
expressing cells. In a mouse model of HTI where the
mouse lethal phenotype was rescued by gene therapy
with either retroviruses or adenoviruses harboring FAH,
tumors and dysplasia were always observed in FAH neg-
ative areas [19, 21]. This is consistent with studies show-
ing that the toxic metabolite in HTI, FAA, is indeed
mutagenic [6] and can induce mitotic abnormalities and
genome instability [22]. FAH-negative cells may be more
prone to cancer development since FAA can accumulate
in these cells while restoration of FAH activity by muta-
tion reversion should remove this toxic metabolite in the
reverted cells thereby reducing the risk of carcinogene-
sis.
The present data show that a dysfunctional allele would
not be transcriptionally silenced in favor of a functional
one since in the reverted region of the liver, the IVS6-1g-
>t transcripts are still detectable. As shown here, the
normal size transcript produced due to reversion of the
Q279R mutation seems to be sufficient to allow FAH ex-
pression in the non-tumoral liver nodules.
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Analysis of the splicing pattern obtained with the minigenes. A- The splicing K7 consists of exon 1 of β-globin and its down-
stream intronic sequences joined to β-globin exon 3 and its upstream intronic sequences. Exon 9, with or without the Q279R
mutation was inserted in K7 at the intronic junction. HeLa cells were transiently transfected with both constructs, the wild-
type Q279Q-K7 and Q279R-containing Q279R-K7. After 24 hours, cells were harvested and the splicing pattern of each mini-
gene was examined by RT-PCR analysis of the transcripts. Exons are represented by boxes and introns by lines. The primers
used for RT-PCR are indicated at each end of the splicing K7. B- Total RNA extracted from transfected HeLa cells was ampli-
fied with HG1S and HG3AS. Plasmidic DNA Q279Q-K7 and Q279R-K7 (pDNA) were also amplified as a control. The band
obtained for Q279Q-K7 transfected cells (RT+) is of expected size, in contrast to the band obtained in the case of Q279R-K7
(RT+) transfected cells, which is of lower molecular weight. RT- serves as a negative control: the reverse transcription reaction
was performed without any enzyme. In the two RT- fractions, the amplification of about 900-bp is due to plasmidic DNA con-
tamination.
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patient and her father [15], as a missense mutation.
However, the complex pattern of transcripts obtained by
RT-PCR in different regions of the liver reported here
suggests that the Q279R mutation could act as a splicing
mutation in vivo. In fact, we identified at least six alter-
native transcripts in the tumoral region and in the pa-
tient's fibroblasts (Figures 2 and 3). Four of these are
produced as a result of the IVS6-1g→t mutation; among
these, three are identical to those previously reported in
other patients harboring this mutation [17]. We also
identified an unreported high molecular weight tran-
script, with a retention of intron 6, as a minor product.
The Q279R mutation seems to be responsible for the oth-
er two transcripts. mRNA analysis in the compound het-
erozygous patient also revealed that this exon 9 mutation
partially affects the splicing at the 5' splice site both in
vivo and in transfected HeLa cells, whereas the IVS6-1g-
>t mutation seems to completely abolish the normal
splicing. Among the abnormal splicing isoforms pro-
duced from either the Q279R or the IVS6-1g->t alleles,
three contain premature termination codons (PTCs) and
are expressed at low levels when compared to the other
major in-frame mRNA transcripts (Figure 3). These
PTC-containing transcripts are likely to be targeted for
nonsense-mediated mRNA decay (NMD; [23,24,25]).
The nucleotide change in the Q279R mutation (836A-
>G) is located at position -2 of the 5' (donor) splice site.
The wild-type adenine at this position is present in 64 %
of all 5' splice sites [26]. The A->G mutation most likely
weakens the splice site, but does not completely abolish
its utilization as demonstrated in the transfection exper-
iments (Figure 4).
Structural analysis of FAH also suggested that the Gln-
>Arg amino acid replacement might be structurally tol-
erated and would not interfere with the structure as pre-
dicted by circular dichroism [27]. Indeed functional
analysis of a Q279R-containing FAH variant showed that
the mutated protein was enzymatically active [27]. Alto-
gether, these data lead to the conclusion that while
Q279R introduces a missense mutation at the cDNA lev-
el, it likely acts as a splicing mutation in vivo thereby in-
hibiting the production of normal FAH mRNA and the
corresponding protein. This is supported by the analysis
of transcripts in the liver and by the minigene assay, but
it cannot be excluded that the mutation is leaky as a low
amount of normal transcripts is found in both cases.
Whether this low amount of FAH mRNA is translated in
sufficient functional protein to alleviate the clinical phe-
notype remains uncertain. While FAH could not be de-
tected in the tumor tissue by western blot analysis, the
presence of low amounts of FAH undetectable by the blot
assay cannot be excluded.
Conclusion
This clinical case of HTI is particularly interesting since
the patient ceased dietary restriction at age 14 and
showed no evidence of sickness until 37 of age. One ex-
planation for this particularly mild phenotype was that
the missense Q279R allele was enzymatically functional
like in the case of the pseudodeficient allele (R341W),
which produces low levels of catalytically active FAH [13,
27, 28]. Our data rather suggest that the Q279R muta-
tion disturbs mRNA splicing in vivo with the result that
very little if any functional mRNA is made. Finally, anal-
ysis of transcripts in a FAH expressing region suggests
that mutation reversion in the Q279R allele leads to the
production of functional FAH and clonal expansion of
the corrected cells and that this restoration may account
for the mild phenotype observed.
Materials and Methods
Case History
The full clinical history of this patient is reported else-
where [15]. Briefly, the patient presented abnormal liver
functions at 9 months of age. She was diagnosed for
chronic tyrosinemia at age 6 with elevated levels of tyro-
sine metabolites. She followed a restrictive diet low in
phenylalanine, tyrosine, and methionine until she was 14
years of age. She was regularly monitored and, except for
high levels of tyrosine, was considered healthy. At age 37,
the patient was diagnosed with hepatocarcinoma and
underwent partial liver resection. She subsequently had
liver transplantation. Frozen and paraffin-embedded liv-
er specimens from a non-tumor and two tumor regions
(T1 and T2) were obtained and analysed. The patient is
heterozygous for mutations IVS6-1g->t (maternal) and
Q279R (paternal) [15].
Detection of the Q279R and IVS6-1g->t mutations in liver 
samples
The presence of the Q279R and IVS6-1g->t mutations in
various regions of the liver (non-tumoral and tumoral)
was verified by PCR analysis. DNA was extracted from
microdissected liver sections as previously described [9].
The IVS6-1g->t mutation was detected with Alu I (New
England Biolabs) using a protocol described in Poudrier
et al., 1999 [29]. For the Q279R mutation, a modified
(bold) forward primer RT75 (5' TGC TGT GCC CAA CCC
GAA CC 3') was designed such as to create, together with
the mutation itself (836A->G), a Msp I (C/CGG) restric-
tion site. Hence the 78-bp PCR product obtained using
RT75 and the reverse primer Tan77 (5' CTG GGT TTG
GGA GCT TCC TGC AGA 3') generates a 58-bp and a 20-
bp fragment specifically from the mutated allele upon
Msp I digestion, whereas the normal allele product re-
mains uncleaved. PCR amplification started with DNA
denaturation at 95°C for 5 min, followed by 30 cycles of:
95°C for 30 s, 63°C for 30 s and 72°C for 30 s. The last
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The PCR product was then digested with Msp I (New
England Biolabs), loaded on a 12 % polyacrylamide gel
and stained with ethidium bromide. The 20-bp Msp I
fragment is not detectable with this method. Mutation
detection tests were performed in triplicates on each re-
gion of the liver with identical results.
RT-PCR
RT-PCR was performed on RNA extracted from dissect-
ed liver sections, EBV transformed lymphocytes [30],
T19 EBV control cells and skin fibroblasts of a different
patient homozygous for IVS6-1g->t. RNA was extracted
using Trizol Reagent (GibcoBRL) as described by the
manufacturer. Two micrograms (2 µg) of total RNA was
incubated at 70°C for 10 min with 500 ng of oligo d(T)12-
18 and then chilled on ice. Reverse transcription was per-
formed at 42°C for 50 min by adding 50 mM Tris-HCl
(pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM DTT, 10 mM
of each dNTP and 200 U SuperScript II reverse tran-
scriptase (GibcoBRL). Raising the temperature to 70°C
for 15 min stopped the reaction. Two microliters (2 µl) of
this cDNA product was used to amplify FAH from exon 2
(forward primer Tan 5, 5'CTG GAC CTC AGC ATC ATC
3') to exon 12 (reverse primer Tan 51, 5' CAG GTT GCA
GCC GTT GAC 3'). The conditions used were 95°C for 5
min, 55°C for 5 min and 72°C for 40 min; 35 cycles of the
following program: 95°C for 30 s, 55°C for 30 s and 72°C
for 1 min 30 s; and a final extension of 15 min at 72°C.
The amplification product was next digested with Sph I
(New England Biolabs) and Pst I (New England Biolabs)
and cloned in pET30FAH [27]. Different clones were se-
lected and sequenced on a 373A DNA sequencer (Ap-
plied Biosystems). A shorter fragment was also amplified
using the forward primer RT76 (5 'CGT GCC TCC TCT
GTC GTG 3 ') located in exon 6 and the reverse primer
Tan51. The amplification was performed as follows: 35
cycles at 95°C for 30 s, 61°C for 30 s and 72°C for 1 min;
and a final extension of 15 min at 72°C.
Minigene constructs and analysis
A fragment surrounding exon 9 was amplified with the
forward primer Tan76 (5'GCA GAT CAG CTC CAG ATT
CTA ATG 3') and the reverse primer RT80 (5'GCT AGC
TGG CAT GTC CAC 3') which contains a Nhe I restriction
site at its 5' end. This amplification was performed on a
normal individual and on the patient's genomic DNA us-
ing the Expand High Fidelity PCR system (Roche Molec-
ular Diagnostics). The conditions used were of 95°C for 5
min, followed by 35 cycles of: 95°C for 30 s, 57°C for 30 s
and 68°C for 1 min 30 s. The last step consisted of an
elongation period of 10 min at 68°C. The fragment ob-
tained was extracted from a 1% agarose gel using the Ul-
traClean TM DNA purification kit (Mo Bio Laboratories,
Inc.). One microliter (1 µl) of purified fragment was am-
plified with RT79 (5' GGT AAC CAT TGA ATG CTC TTG
C 3'), which was modified at its 5' end to create a Bst EII
restriction site and RT80 (see above). The PCR amplifi-
cation started with a denaturation step of 5 min at 95°C
followed by 30 cycles of: 95°C for 30 s, 56°C for 30 s and
68°C for 1 min. The final elongation step was of 5 min at
68°C. The 387-bp expected fragment was purified from a
2% agarose gel and digested with Bst EII (New England
Biolabs) and Nhe I (New England Biolabs) and cloned in
K7, a minigene cassette containing human β-globin ex-
ons 1 and 3 (Deguillien, M., Huang, S. C., Morinière, M.,
Dreumont, N., Benz, E. J. Jr and Baklouti, F., unpub-
lished). The two minigenes obtained (Q279Q-K7 and
Q279R-K7) were sequenced on a 373A DNA sequencer.
One point six micrograms (1.6 µg) of each construction
were cotransfected with 0.4 µg of pEGFP-NI (Clontech)
using Lipofectamine (Gibco BRL). The efficiency of
cotransfection was respectively of 20% and 30% for
Q279Q-K7 and Q279R-K7. After 24 hours, cells were
harvested and lysed in Trizol Reagent. Total RNA was di-
gested with 1 µl of RNase-free DNase I (Boehringer-
Manheim) for 30 min at 37°C. RNA was extracted for a
second time with 1 ml Trizol Reagent and resuspended in
50 µl of RNA storage solution (Ambion, Inc.). Reverse
transcription was performed on 2 µg of total RNA in a fi-
nal volume of 40 µl with 2 µl of the M-MLV reverse tran-
scriptase (Gibco-BRL) and 1 µg of oligo (dT) 12-18,
according to the manufacturer's recommendations. Two
microliters (2 µl) of reverse transcription product were
amplified using Taq polymerase (Pharmacia Biotech.).
The forward primer HG1S (5' TAG CGG CCG CAT ATA
AGT CAG GGA AGA GCC A 3') and the reverse primer
HG3AS (5' TAT CTA GAG TTG GAC TTA GGG AAC AAA
3') are located at each extremity of the splicing cassette.
The PCR amplification was performed as follows: a dena-
turation step of 5 min at 95°C, followed by 35 cycles of:
95°C for 30 s, 61°C for 30 s and 72°C for 1 min. The final
elongation step was 10 min a 72°C. The splicing products
were extracted from the agarose gel and sequenced.
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